<DOC>
	<DOCNO>NCT02159820</DOCNO>
	<brief_summary>Ovarian cancer lethal gynecological cancer 5th lead cause cancer death woman . Most patient typically diagnose advanced-stage disease . Platinum-paclitaxel regimen widely adopt standard first-line treatment advanced ovarian cancer . Multiple collaborative randomise phase III trial evaluate addition third chemotherapy agent , maintenance therapy alternative taxanes fail demonstrate significant improvement standard carboplatin/taxane doublet . Decitabine ( DAC ) , one major DNA demethylating agent , approve treatment preleukemic hematological disease myelodysplastic syndrome ( MDS ) Food Drug Administration . Past trial high dos , i.e. , use maximal tolerate dose , patient solid tumor show low therapeutic index , due extreme toxicity probably confound ability document true clinical response . Low dose DNA demethylation agent decitabine ( DAC ) resensitize therapeutic index resistent ovary cancer cell vivo vitro . The investigator hypothesize DAC-triggered epigenetic reprogramming tumor cell possible immune cell could induce pronounced long-dated clinical effect chemosensitization- immunopotentiation-driven maximal eradicate role minimal/residual lesion primary patient poor prognosis .</brief_summary>
	<brief_title>Lower Dose Decitabine ( DAC ) -Primed TC ( Carboplatin-Paclitaxel ) Regimen Ovary Cancer</brief_title>
	<detailed_description>Given poor prognosis currently exist therapeutic strategy , The investigator perform prospective , randomize , phase II III , intergroup trial compare carboplatin plus paclitaxel ( TC ) DAC-primed TC ( DTC ) regimen previously untreated patient stage II IV ovarian cancer .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Decitabine</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<criteria>Patients histologically confirm International Federation Gynecology Obstetrics ( FIGO ) stag II IV fallopian tube cancer , primary peritoneal cancer . If result cytological examination available , patient need follow criterion : cytological diagnosis adenocarcinoma ; abdominal mass 2 cm diameter abdominal image ; CA125 carcinoembryonic antigen ( CEA ) ratio10 25 , evidence gastrointestinal cancer CA125/CEA ratio less equal 25 . Previous chemotherapy allow . All patient least 18 year age , Eastern Cooperative Oncology Group ( ECOG ) performance status 03 , require adequate hematologic , renal , hepatic function . Patients exclude ovarian tumour low malignant potential , synchronous metachronous ( within 5 year ) malignant disease carcinoma situ .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>June 2014</verification_date>
</DOC>